Related Experiment Video

Updated: Aug 6, 2026

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein
10:43

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein

Published on: December 3, 2010

22.3K

Palmarumycin P3 Reverses Mrr1-Mediated Azole Resistance by Blocking the Efflux Pump Mdr1

Minghui Song1, Ming Zhang2, Jinghui Lu1

  • 1Department of Natural Product Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.

Antimicrobial Agents and Chemotherapy
|January 18, 2022
PubMed

Insights

Palmarumycin P3 (PP3) reverses antifungal resistance in Candida strains by reducing MDR1 transcription. This compound also inhibits drug efflux, making it a potential therapeutic agent against resistant fungal infections.

Area of Science:

  • Medical Mycology
  • Molecular Biology
  • Drug Discovery

Background:

  • Azole antifungal drugs are crucial for treating Candida infections.
  • Multidrug resistance (MDR) in Candida, often mediated by the MDR1 gene and transcription factor Mrr1, limits treatment efficacy.
  • Novel strategies are needed to overcome azole resistance in clinical fungal pathogens.

Purpose of the Study:

  • To investigate the potential of Palmarumycin P3 (PP3) in reversing azole resistance in Candida.
  • To elucidate the mechanism by which PP3 affects MDR1 transcription and drug efflux.

Main Methods:

  • Testing PP3's effect on the susceptibility of Candida albicans strains with Mrr1 gain-of-function mutations.
  • Assessing PP3's impact on the efflux of Mdr1 substrates.
  • Utilizing molecular docking to predict PP3's interaction with the Mdr1 transporter.

Main Results:

  • PP3 successfully restored susceptibility to multiple antifungal drugs in resistant Candida albicans strains.
  • PP3 demonstrated inhibition of Mdr1 substrate efflux in strains with hyperactive MRR1 alleles.
  • Molecular docking suggested PP3 acts as an Mdr1 blocker by binding to its substrate-binding pocket.

Conclusions:

  • Palmarumycin P3 is effective in reversing azole resistance in clinical Candida strains.
  • PP3 functions by downregulating MDR1 transcription and inhibiting Mdr1-mediated drug efflux.
  • PP3 represents a promising therapeutic lead for combating drug-resistant fungal infections.
Keywords:
Candida albicansMdr1Mrr1azole resistancepalmarumycin P3

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis09:44

Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis

Published on: June 13, 2021

2.8K

Related Concept Videos

Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...